Seismic Therapeutic Launches With $101 Million Series A Financing To Usher In A New Era Of Immunology Drug Development Integrating Machine Learning
Feb 09, 2022•over 3 years ago
Amount Raised
$101 Million
Round Type
series a
Description
Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced its launch and financing of $101 million. The Series A was led by Lightspeed Venture Partners with participation from lead founding investors Timothy A. Springer and Polaris Partners, along with new investors GV, Boxer Capital, Samsara BioCapital, and management and founders. Seismic’s IMPACTTM platform systematically integrates machine learning, structural biology, protein engineering and translational immunology to invent novel biologics and optimize properties with significantly improved efficiency and scale over conventional therapeutics discovery
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech